Gaucher disease types 1 and 3: Phenotypic characterization of large populations from the ICGG Gaucher Registry

American Journal of Hematology

Volumn 90, Issue S1, 2015, Pages S12-S18

  Grabowski, Gregory A ^a   Zimran, Ari ^b   Ida, Hiroyuki ^c  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b HEBREW UNIVERSITY   (Israel)

^c JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BONE DISEASE; CHILD GROWTH; CLINICAL TRIAL (TOPIC); GAUCHER DISEASE; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HEMATOLOGICAL PARAMETERS; HUMAN; LIVER WEIGHT; LUNG DISEASE; PHENOTYPE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; REVIEW; SPLEEN; CLASSIFICATION; GENETICS; PATHOLOGY; REGISTER;

GAUCHER DISEASE; HUMANS; PHENOTYPE; REGISTRIES;

EID: 84932136637     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24063     Document Type: Review

References (53)

1. Sibille A, Eng CM, Kim SJ, et al. Phenotype/genotype correlations in Gaucher disease type I: Clinical and therapeutic implications. Am J Hum Genet 1993;52:1094-1101.
2. Zimran A, Gelbart T, Westwood B, et al. High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 1991;49:855-859.
3. Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992;71:337-353.
4. Zimran A, Sorge J, Gross E, et al. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 1989;2:349-352.
5. Grabowski G, Kolodny E, Weinreb N, et al. Gaucher disease: Phenotypic and Genetic Variation. In: Scriver C, Beaudet A, Sly W, Valle D, editors. The Metabolic and Molecular Bases of Inherited Diseases. New York: McGraw-Hill; 2006. http://ommbid.mhmedical.com/
6. Grabowski G, Petsko G, Kolodny E. Gaucher disease. Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, and Sly WS editors, The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill; 2010. http://ommbid.mhmedical.com/
7. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: Demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000;160:2835-2843.
8. Charrow J, Andersson HC, Kaplan P, et al. Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: Consensus recommendations. J Pediatr 2004;144:112-120.
9. Charrow J, Esplin JA, Gribble TJ, et al. Gaucher disease: Recommendations on diagnosis, evaluation, and monitoring. Arch Intern Med 1998;158:1754-1760.
10. Moscicki R. Dosage regimens of alglucerase in Gaucher disease: A comparison of the rate and extent of clinical response. ICGG Regis Update 1995;1995:1-11.
11. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4-14.
12. Weinreb NJ, Aggio MC, Andersson HC, et al. Gaucher disease type 1: Revised recommendations on evaluations and monitoring for adult patients. Semin Hematol 2004;41:15-22.
13. Weinreb NJ, Goldblatt J, Villalobos J, et al. Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis 2013;36:543-553.
14. Grabowski GA, Hopkin RJ. Enzyme therapy for lysosomal storage disease: Principles, practice, and prospects. Annu Rev Genomics Hum Genet 2003;4:403-436.
15. Sidransky E. Gaucher disease: Complexity in a "simple" disorder. Mol Genet Metab 2004;83:6-15.
16. Balwani M, Fuerstman L, Kornreich R, et al. Type 1 Gaucher disease: Significant disease manifestations in "asymptomatic" homozygotes. Arch Intern Med 2010;170:1463-1469.
17. Mistry PK, Weinreb NJ, Kaplan P, et al. Osteopenia in Gaucher disease develops early in life: Response to imiglucerase enzyme therapy in children, adolescents and adults. Blood Cells Mol Dis 2011;46:66-72.
18. Khan A, Hangartner T, Weinreb NJ, et al. Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease-A study from the international collaborative Gaucher group (ICGG) Gaucher registry. J Bone Miner Res 2012;27:1839-1848.
19. Erduran E, Mocan H, Gedik Y, et al. Hydrocephalus, corneal opacities, deafness, left ventricle hypertrophy, clinodactyly in adolescent patient. A new syndrome associated with glucocerbrosidase deficiency. Genet Couns 1995;6:211-215.
20. Uyama E, Takahashi K, Owada M, et al. Hydrocephalus, corneal opacities, deafness, valvular heart disease, deformed toes and leptomeningeal fibrous thickening in adult siblings: A new syndrome associated with beta-glucocerebrosidase deficiency and a mosaic population of storage cells. Acta Neurol Scand 1992;86:407-420.
21. Chabas A, Gort L, Montfort M, et al. Recurrence of the D409H mutation in Spanish Gaucher disease patients: Description of a new homozygous patient and haplotype analysis. J Med Genet 1998;35:775-777.
22. George R, McMahon J, Lytle B, et al. Severe valvular and aortic arch calcification in a patient with Gaucher's disease homozygous for the D409H mutation. Clin Genet 2001;59:360-363.
23. Tylki-Szymanska A, Keddache M, Grabowski G. Characterization of neuronopathic Gaucher disease among ethnic poles. Genet Med 2006;8:8-15.
24. Oliveira F, Alegra T, Dornelles A, et al. Quality of life of Brazilian patients with Gaucher disease and Fabry disease. J Inherit Metab Dis Rep 2013;7:31-33.
25. Adelino T, Martins G, Gomes A, et al. Biochemical and molecular chitotriosidase profiles in patients with Gaucher disease type 1 in Minas Gerais, Brazil: New mutation in chit1 gene. J Inherit Metab Dis Rep 2013;9:85-91.
26. Doneda D, Lopes A, Oliveira A, et al. Gaucher disease type I: Assessment of basal metabolic rate in patients from Southern Brazil. Blood Cells Mol Dis 2011;46:42-46.
27. Sobreira E, Pires RF, Cizmarik M, et al. Phenotypic and genotypic heterogeneity in Gaucher disease type 1: A comparison between Brazil and the rest of the world. Mol Genet Metab 2007;90:81-86.
28. Bembi B, Zambito Marsala S, Sidransky E, et al. Gaucher's disease with Parkinson's disease: Clinical and pathological aspects. Neurology 2003;61:99-101.
29. Eblan M, Walker J, Sidransky E. The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 2005;352:728-731.
30. Goker-Alpan O, Schiffmann R, LaMarca ME, et al. Parkinsonism among Gaucher disease carriers. J Med Genet 2004;41:937-940.
31. Machaczka M, Rucinska M, Skotnicki AB, Jurczak W. Parkinson's syndrome preceding clinical manifestation of Gaucher's disease. Am J Hematol 1999;61(3):216-7.
32. Sidransky E. Gaucher disease and Parkinsonism. Mol Genet Metab 2005;84:302-304.
33. Wong K, Sidransky E, Verma A, et al. Neuropathology provides clues to the pathophysiology of Gaucher disease. Mol Genet Metab 2004;82:192-207.
34. Lwin A, Orvisky E, Goker-Alpan O, et al. Glucocerebrosidase mutations in subjects with parkinsonism. Mol Genet Metab 2004;81:70-73.
35. Mazzulli J, Xu Y, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011;146:37-52.
36. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009;361:1651-1661.
37. Kaplan P, Andersson HC, Kacena KA, Yee JD. The clinical and demographic characteristics of nonneuronopathic gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med 2006;160:603-608.
38. Grabowski GA. Gaucher disease: Gene frequencies and genotype/phenotype correlations. Genet Test 1997;1:5-12.
39. Mao R, O'Brien JF, Rao S, et al. Identification of a 55-bp deletion in the glucocerebrosidase gene in Gaucher disease: Phenotypic presentation and implications for mutation detection assays. Mol Genet Metab 2001;72:248-253.
40. Walley AJaHA. A novel point mutation (D380A) and a rare deletion (1255del55) in the glucocerebrosidase gene causing Gaucher's disease. Hum Mol Genet 1993;2:1737-1738.
41. Fairley C, Zimran A, Phillips M, et al. Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: An analysis of 798 patients from the ICGG Gaucher registry. J Inherited Metab Dis 2008;31:738-744.
42. Liou B, Kazimierczuk A, Zhang M, et al. Analyses of variant acid beta-glucosidases: Effects of Gaucher disease mutations. J Biol Chem 2006;281:4242-4253.
43. Liou B. Mechanistic studies of normal and mutant acid β-glucosidases, MS Thesis. Developmental Biology. Cincinnati, Ohio: University of Cincinnati; 1996.
44. Weinreb NJ, Charrow J, Andersson HC, et al. Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: A report from the Gaucher Registry. Am J Med 2002;113:112-119.
45. Kuczmarski R, Ogden C, Grummer-Strawn L, et al. CDC growth charts: United States. Adv Data 2000;314:1-27.
46. Andersson HC, Charrow J, Kaplan P, et al. Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105-110.
47. Baldellou A, Andria G, Campbell PE, et al. Paediatric non-neuronopathic Gaucher disease: Recommendations for treatment and monitoring. Eur J Pediatr 2004;163:67-75.
48. Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122:1182-1190.
49. Mistry PK, Sirrs S, Chan A, et al. Pulmonary hypertension in type 1 Gaucher's disease: Genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-98.
50. Hoeper M, Niedermeyer J, Hoffmeyer F, et al. Pulmonary hypertension after splenectomy? Ann Intern Med 1999;130:506-509.
51. Dreborg S, Erikson A, Hagberg B. Gaucher disease-Norrbottnian type. I. General clinical description. Eur J Pediatr 1980;133:107-118.
52. Tylki-Szymanska A, Millat G, Maire I, Czartoryska B. Types I and III Gaucher disease in Poland: Incidence of the most common mutations and phenotypic manifestations. Eur J Hum Genet 1996;4:334-337.
53. Tylki-Szymanska A, Vellodi A, El-Beshlawy A, et al. Neuronopathic Gaucher disease: Demographic and clinical features of 131 patients enrolled in the International Collaborative Gaucher Group Neurological Outcomes Subregistry. J Inherit Metab Dis 2010;33:339-346.